CN103547240A - Systems and methods for balancing and maintaining the health of the human autonomic nervous system - Google Patents
Systems and methods for balancing and maintaining the health of the human autonomic nervous system Download PDFInfo
- Publication number
- CN103547240A CN103547240A CN201180070951.0A CN201180070951A CN103547240A CN 103547240 A CN103547240 A CN 103547240A CN 201180070951 A CN201180070951 A CN 201180070951A CN 103547240 A CN103547240 A CN 103547240A
- Authority
- CN
- China
- Prior art keywords
- supplement
- neurotransmitter
- therapy system
- patient
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
Abstract
A protocol or procedure is provided for lowering sympathetic nervous system arousal in a person in order to prepare that person for a medical or dental procedure. First, a therapeutic dosage of one or more neurotransmitter supplements, such as a gamma aminobutyric acid formulation, a tryptophan-derived neurotransmitter precursor, and dehydroepiandrosterone are administered to the patient. Concomitantly, gelled electrodes are placed adjacent or below the mastoid. The gelled electrodes are connected to a cranial electrotherapy stimulation device that administers a sub-sensation level current to the patient. Also, a noise dampening headset is placed on the patient and a neuroacoustic entrainment recording or program is played. Next, light is blocked with black out glasses. Then, the medical or dental procedure is performed.
Description
Technical field
The present invention relates to medical treatment and dental care, more particularly, the anxiety that relates to the sympathetic nervous system awakening that is designed to reduce in human body reduces therapeutic scheme.
Background technology
Have and unnecessary and inappropriately about medical treatment and the fear of dental treatment and the individual of anxiety, often refuse needed medical treatment and dental care.Even when this individual consent is medically treated or during dental operation, their fear and anxiety can make to experience unnecessarily unhappy, cause the medical outcome of suboptimum.Therefore, need a kind of method of alleviating and correcting from anxiety and fear that provides to individual for the preparation for medical treatment or dental operation.
Summary of the invention
Provide the awakening of fast reducing sympathetic nervous system in human body to make this human body be ready to be medically treated or therapeutic scheme or the process of dental operation, and this therapeutic scheme or process allow to return to rapidly pre induction (pre induction) state.First, give patient oral or sublingual administration therapeutic dose, such as the derivative tryptic hydrolysate precursors of neurotransmitters of precursors of neurotransmitters, casein of gamma-aminobutyric acid analog, 4-Amino-3-phenylbutyric acid (Phenibut) analog, tryptophan and one or more precursors of neurotransmitters and the analog supplement of dehydroepiandrosterone (DHEA).Thereupon, gelation electrode is placed on mastoid process contiguous or under.Gelation electrode is connected to cranium electricity treatment stimulating apparatus, and this cranium electricity treatment stimulating apparatus applies the electric current of the lower level (sub-sensation level) of sensation to patient.In addition, noise suppressed headband receiver is placed on to patient and goes up and play neural acoustics traction software recording or program.Next, use sunglasses to shut out the light.Then, carry out medical treatment or dental operation.
Accompanying drawing explanation
Fig. 1 is illustrated in for realizing the schematic block diagram of the system basic building block of therapeutic scheme of the present invention.
Fig. 2 is a flow chart, for the method step being associated with the process of carrying out therapeutic scheme of the present invention is shown.
Fig. 3 is a chart, for physiology labelling and the marker characteristic under sympathetic nerve and parasympathetic stimulation of the curative effect that confirms therapeutic scheme of the present invention are shown.
Fig. 4 is bar diagram, for being illustrated in the statistical remarkable trend of the physiology labelling in the situation of applying therapeutic scheme of the present invention.
Fig. 5 is bar diagram, for the GSR response of complete treatment scheme and part therapeutic scheme is shown.
Fig. 6 is bar diagram, for illustrating the BVP amplitude response of complete treatment scheme and part therapeutic scheme.
Fig. 7 A and 7B illustrate the figure of complete treatment scheme to the variations in temperature of baseline.
Fig. 8 is bar diagram, for the HRV amplitude response of complete treatment scheme and part therapeutic scheme is shown.
Fig. 9 is bar diagram, for the %HF response of complete treatment scheme and part therapeutic scheme is shown.
Figure 10 is bar diagram, for the %LF response of complete treatment scheme and part therapeutic scheme is shown.
Figure 11 is bar diagram, for the SDNN response of complete treatment scheme and part therapeutic scheme is shown.
Figure 12 is bar diagram, for the RMSSD response of complete treatment scheme and part therapeutic scheme is shown.
Figure 13 is bar diagram, for the SCP response of complete treatment scheme and part therapeutic scheme is shown.
Figure 14 is bar diagram, for the β amplitude response of complete treatment scheme and part therapeutic scheme is shown.
Figure 15 is bar diagram, for the δ amplitude response of complete treatment scheme and part therapeutic scheme is shown.
Figure 16 is bar diagram, exceeds the % response of θ for the α of complete treatment scheme and part therapeutic scheme is shown.
The specific embodiment
Although following detail has been described the various aspects in various embodiment of the present invention, but the rational technique personnel of this area will recognize, in the situation that not departing from appending claims defined the spirit and scope of the present invention, can in details of the present invention, make various changes.Therefore, should be appreciated that, unless otherwise prescribed, the present invention is not limited to the detail that illustrates and describe here.
Fig. 1 is the figure that the member of therapeutic scheme 10 of the present invention is shown.In Fig. 1, patient 12 receives noise suppressed stereophone 16, the dimmed eyeshield 18 of vision, cranium electrostimulator electrode 22 and neurotransmitter supplement 24.Neural acoustics traction signal generator 14 is connected to patient 12 by earphone 16.Cranium electricity treatment stimulating instrument 20 is connected to patient 12 by CES electrode 22.
Fig. 2 is for allowing patient be ready to be medically treated or the flow chart of an embodiment of the step of the therapeutic scheme of the present invention of dental operation.This method is reduced in rapidly sympathetic nervous system awakening in human body, to allow that people be ready to be medically treated or dental operation.Patient should planned operation be advanced to many 40 minutes arrival clinics.When being ready to begin treatment scheme 30, patient is sitting in comfortable chaise longue 32.Take the similar thing/precursor of one or more neurotransmitteies supplement of therapeutic dose to patient 34.For example, give patient's sublingual administration gamma-aminobutyric acid analog preparation (GABAa and GABAb agonist) 36, derivative neurotransmitter 38 and the dehydroepiandrosterone 40 of tryptophan.In an alternate embodiment, can take the similar thing/precursor of neurotransmitter supplement with white form, this frost is applied by transdermal, is preferably applied to the neck area on carotid artery, and is applied to the region in each ear in vagal Arnold branch (ear branch).Thereupon, in step 42, gelation electrode 22 is placed contiguously or lower than mastoid process.Gelation electrode 22 is connected to patient and applies and feel that the cranium electricity treatment of lower horizontal electric current stimulates (CES) to install 20, and optional intervalometer makes CES device 20 to patient, apply electric current on continuous or intermittent basis.On patient, place noise suppressed earphone 16, and play neural acoustics traction recording or program 44.In step 46, carry out medical treatment or dental operation.
In one embodiment, only before dentistry or medical operating and not during implement that the treatment of cranium electricity stimulates, neural acoustics traction program and the similar thing/precursor of neurotransmitter additional project.In another embodiment, during dentistry or medical operating, if it is tediously long particularly to perform the operation, continue to apply that the treatment of cranium electricity stimulates, one or more in neural acoustics traction software program and the similar thing/precursor of neurotransmitter additional project.As shown in Figure 2, if necessary, can give the similar thing/precursor of the extra neurotransmitter of 52 patients supplement.When this operation stops 54, stopping 56 cranium electricity treatments stimulates and neural acoustics traction program, and finishes 58 therapeutic schemes.
The invention discloses that the treatment of the similar thing/precursor of neurotransmitter supplement, cranium electricity stimulates and neural acoustics traction software follow bestow for loosen and the stimulation of the peaceful neurotransmitter of feeling the to be associated chemical substance of the impulsion of synapse transmission (that is, across) has cooperative compensating effect.Paragraph has below been described for being about to be medically treated or the patient of dental operation implements importance, object and the benefit of these complementary schemes.
The neurobiology of pressure and awakening
The several systems of human body participate in the reaction to pressure, comprise sensation thalamus, sensory cortex, hippocampus, corpus amygdaloideum, hypothalmus-pituitary-adrenal axis (hpa axis) and autonomic nervous system (ANS consists of sympathetic nervous system (SNS) and parasympathetic nervous system (PNS)).In response to showing dangerous sensory stimuli, sensation thalamus exchanges with corpus amygdaloideum by two approach.Thalamus directly also exchanges to corpus amygdaloideum immediately by cortex underpass, and without any the cognition of intervening.Thalamus also by cortex and hippocampus and corpus amygdaloideum indirectly with more slowly exchange.Store conscious memory and provide the hippocampus of environmental information and whether threat that the cortex relevant to cognition told corpus amygdaloideum perception is real.
Corpus amygdaloideum storage implicit memory, such as the response with good conditionsi of the memory for aversive stimulus and the emotion relevant with fear.It comprises several approach physically but in function different core.Outside the substrate of corpus amygdaloideum, complex is processed the input from sensory system, and perception and the significance of assessing the threat being applied by this sensory system input.Its main output is the central nucleus that participates in the corpus amygdaloideum of emotion awakening.This central nucleus sends frightened signaling burst to hypothalamus then.
In response to frightened signaling burst, hypothalamus discharges a kind of pressure hormone that is called as corticotropin-releasing factor (CRF), it is the adrenocortical hormone (ACTH) of Stimulation of The Brain hypophysis release pressure hormone again then, it then again in stimulation of renal gland cortex to blood flow, discharge corticosteroid hormone.Such as the corticosteroid hormone of hydrocortisone for development health for danger fight or flight reaction be important.
In response to frightened signaling burst, hypothalamus also activates sympathetic nervous system (SNS).Uncomfortable anxiety symptom is responsible in high SNS awakening.SNS prepares health immediately and energetic defence behavior by following manner: tighten up muscle; Vasoconstrictive; Increase heart rate, metabolism and blood pressure and blood sugar level; The expansion pupil of eyes and the trachea and bronchus of pulmonary; Shunting blood is to skeletal muscle, liver, brain and the heart; Stimulate adrenal gland; And stimulate liver that glycogen is converted to glucose.On the contrary, the heart beating of slowing down, shrinks bronchus to parasympathetic nervous system (PNS), and usually physical recovery is arrived to normal condition.
The neurotransmitter effect that SNS and PNS link up by the nervous pathway along SNS and PNS.Each of SNS and PNS comprises (1) preganglionic neuron, and it is connected to central nervous system (CNS) neuroganglion of health; And (2) move towards the postganglionic neuron of effector organ from neuroganglion.
Preganglionic sympathetic neuron discharges excited neurotransmitter acetylcholine, and Postganglionic sympathetic neuron discharges norepinephrine (being also referred to as norepinephrine).Because each neural SPN forms synapse with many postganglionic neurons conventionally, and because some neurons directly discharge norepinephrine and epinephrine (also referred to as epinephrine) in blood, so the activation of SNS affects several body functions conventionally simultaneously.
As mentioned above, the nervous system of the physiological human body of participation pressure and anxiety exchanges with neurotransmitter.Two inhibitory neurotransmitters the most outstanding are γ-aminobutyric acid (GABA) and 5-hydroxy tryptamine.GABA is the main inhibitory neurotransmitter of central nervous system.GABA receptor finds on the 25-40% of brain synapse.When GABA is attached to GABA receptor, it opens chloride channel, and it allows electronegative chloride ion to enter the inside of neurocyte.This makes neuron polarization then, to forbid that the presynaptic of further neurotransmitter discharges.By suppressing neural discharge, GABA suppresses the message that anxiety is relevant and arrives cortex.
When being subject to long-term pressure or anxiety, brain exhausts the storage of its available GABA and other inhibitory neurotransmitters.This can finally cause full-blown anxiety or panic attack, with excessive sweating, tremble, muscular tone, weak, obnubilation, dyspnea, fear and other symptoms.
5-hydroxy tryptamine is a kind of neurotransmitter producing by being arranged in the nucleus ceruleus of brain and the neuron of rapheal nuclei.Nucleus ceruleus and rapheal nuclei domination thalamus, cerebral cortex and hippocampus.Low-level 5-hydroxy tryptamine is associated with depression, anxiety, insomnia, impulsive behavior, invasion and violent behavior.
Neurotransmitter supplements
In the use of the precursors of neurotransmitters supplement of the therapeutic dose of the preferred embodiments of the present invention, by the anxiety of alleviating anxiety and reducing patient, there is the angst resistance effect to brain.
In one embodiment, the amino acid preparation of the therapeutic dose that doses a patient with, it comprises: the magnesium of 1-6 milligram (with the form of Magnesium taurinate .); The GABA of 50-200 milligram and phenyl-γ-aminobutyric acid; The glycine of 10～80 milligrams; The N-acetyl-L-tyrosine of 10～40 milligrams; And, the 5-20 milligram taurine form of Magnesium taurinate. (also with).In this preparation, contain three the additional N-acetyl group of main inhibitory neurotransmitter TYRs, N-acetyl group TYR is the precursor of another kind of neurotransmitter norepinephrine.Said preparation is inhibited for the neuron of brain together, and has therefore reduced the awakening of sympathetic nervous system.Preferably with one or more, chew or the form of sublingual tablet or sublingual administration anti-fatty liver spray is taken said preparation.By sublingual administration said preparation, said preparation is absorbed directly into blood by the blood vessel under tongue and in two cheeks, allows said preparation be input to fast in system and pass through blood brain barrier.
In a second embodiment, a kind of neurotransmitter supplementing preparation that doses a patient with, the combination that it contains following compositions: vitamin B6, vitamin C, bioflavonoids and tryptophan or L-5-hydroxytryptophan (L-5-HTP) and casein tryptic hydrolysates (CTH).The L-thiamine that the therapeutic dose of such combination contains 25-400 milligram, L-5-hydroxytryptophan, the 2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine .-5 '-phosphate ester (that is, vitamin B6) of 20-100 milligram and the CTH of 100-800 milligram ascorbic acid (being vitamin C) and 5-500 milligram of 10～150 milligrams.Patient may determine actual close rate for self response of therapeutic scheme.Amino acid preparation as above is such, and 5-hydroxy tryptamine promotes preparation and preferably by one or more tablets or lipotropic spray Sublingual, takes.Or the form of the enteric coatings capsule of Gong swallowing to anticipate is taken it.Enteric coatings makes capsule walk around enzyme under one's belt, and this enzyme converts too early L-5-HTP to 5-hydroxy tryptamine before arriving central nervous system.
The derivative precursors of neurotransmitters of tryptophan is as the synthetic precursor for 5-hydroxy tryptamine (that is, 5HTP or 5-HTP) and melatonin (melatonin).Vitamin B6 is for 5HTP enzyme being converted to the cofactor of 5-hydroxy tryptamine, and Catalyzed by Vitamin C tryptophan is to the hydroxylating of 5-hydroxy tryptamine.
In the 3rd embodiment, the dehydroepiandrosterone that doses a patient with (DHEA).Nature is a signal indicator by the hormone dehydroepiandrosterone of acth secretion, and it reduces the level of pressure hormone hydrocortisone in vivo.This increase to preparation provides individual some whole bodies in Chronic Pressure and/or anxiety to discharge.
Preferred embodiment is bestowed the part or all of combination of above-mentioned supplement.
Neural acoustics traction
To in the preferred embodiments of the present invention in conjunction with neural acoustics traction software be intended to arouse with produce lax, some frequency of brain wave that dissociates relevant with the first stage of sleeping.
The electrochemical activity of brain produces measurable electromagnetic form.The electroencephalogram of brain (EEG) can quantize this activity aspect amplitude and frequency.Research is associated different brain wave frequencies from different mental statuss.Frequency between 13 and 40 hertz (that is, β E.E.G) is located, and brains is active, vigilance also can be absorbed in details.β E.E.G state is associated with dialogue and emulative physical exertion.Between 8 and 13 hertz (that is, alpha state), brains more loosens and reacts fast.Alpha state with creativity, ponder with visual and be associated.The θ E.E.G state moving in the scope of 4 to 8 hertz and daydream, powerful creativity, visual capacity, meditate and go out body experience and be associated.Brain cell their ratio of sodium and potassium of resetting in θ state, what sleep this contributes to be interpreted as is very important for healthy mental function.The δ E.E.G state moving in the scope of 0.5 to 4 hertz is with unconscious, very dark and be associated with longterm memory without the sleep of dream.Some have the meditation individual of experience and discipline can both train their brains to move in δ state in the conscious while very much.
The brain of a normal Healthy People is on whole daytime and cycle through each of these E.E.G states evening.And, because be not that all positions of brain are active equally at any time, so brain moves conventionally simultaneously in several E.E.G states.A people's state of mind or level of consciousness are associated with prevailing E.E.G state conventionally.
Also believe, other brain wave frequencies of the frequency ratio of some E.E.Gs promote production and the transmission of some neurotransmitter more.The brainwave patterns of 10Hz is associated with generation and the turnover of the reinforcement of 5-hydroxy tryptamine.For this reason, can believe, by by brain traction to given frequency, can strengthen the generation of some neurotransmitteies.
There is the whole bag of tricks of traction E.E.G state, comprise discipline meditation, recite scripture and hypnosis.Most methods is aroused brain for the response a given E.E.G state operation by following manner: make brain stand repetitive stimulation, as the pulse of sound, volume modulation, monaural beat, ears beat or light pulse.10 hertz of stimulations of the constant repetition applying to brain can stimulate the E.E.G state of 10 hertz.This phenomenon is called as " frequency is followed response ".
In the preferred embodiment of the present invention, noise suppressed earphone is placed on patient's ear, and is connected to neural acoustics traction recording (being numerical software file in a preferred embodiment).In one embodiment, recording preferably includes sound or music, and it arouses higher levels of α or θ E.E.G and reduce β brain wave frequency place and carry out volume modulation being designed.
In another embodiment, recording is designed to make the one or more ears beats of brain perception.When presenting respectively one, the signal of two kinds of different frequencies and each ear, ears beat occurs.Each ear is hardwired to the hard Nux Canarii albi (the acoustic processing center of brain) in corresponding cerebral hemisphere.Brain is attempting to be in harmonious proportion perception " ears beat " the different noise that it hears from each ear.If to an ear frequence of exposure 100Hz, and to 105 hertz of another frequence of exposures, brain is the ears beat of perception 5Hz, and finally may be by traction at this ears beat frequency place resonance.
In a preferred embodiment of the invention, neural acoustics traction software application is introduced the recording of a plurality of ears frequencies, and this recording preferably has the form of the ears frequency of harmonic wave layering and patterning.By this way, in brain, trigger a plurality of frequencies and follow response simultaneously.In addition, preferably, the ears frequency of neural acoustics traction software and instrumental music, rain make the relieved sound of people or naturally together with sound mixture.
The treatment of cranium electricity stimulates
In the preferred embodiments of the present invention, in conjunction with the treatment of cranium electricity, stimulate (CES) to be intended to stimulate in the release of neural irritability and inhibition class neurotransmitter and the balance in transmission.Be also referred to as micro-electric current electricity irritation or be to apply low-level pulsed electric current to head through the CES of cranium microelectric current.Preferably, via in mastoid process or under conducting resinl electrode to patient's delivered current.
Preferably the form with the square wave pulse of sinusoidal, rectangle or modification provides electric current.Frequency is arranged between 0.1 and 1,000 hertz, selects and is superimposed upon up on the carrier wave of 150 kilo hertzs.Waveform is two-phase and ambipolar preferably, and has 20% to 50% dutycycle.Current intensity is set at the maintenance level (, between 0.01mA and 7mA, being for example, more preferably about 0.1mA) of threshold of feelings below.CES device 240 should be able to be adjusted for changing the voltage of the resistance of level, to the electric current of maintenance level is provided.CES is preferably applied at least 30 minutes, and reaches 6 hours.The pattern of can adjusting frequency every now and then and levels of current are to prevent physiological regulation.
CES is considered to vagus nerve stimulation, thus and promotion PNS dominance.CES is the hypothalamus region at brain by current focusing also, and wherein, it affects the nerves, and presynaptic of mediator discharges and the postsynaptic receives both.Electric current increases the cell leakage of brain cell by low-level electrophoresis, this low-level electrophoresis improves the absorption of neurotransmitter.Electric current is increased in 5-hydroxy tryptamine and the endorphins level in brain, and is reduced in the level of the pressure hormone hydrocortisone in brain.It also promotes alpha state.Believe that it is by stimulating the neuron of brain to accelerate their inhibition with identical speed and manufacture and the reception of excitatory neurotransmitter moves, thereby make them mutually suppress the other side's further generation, neurotransmitter is returned to the homoiostasis before pressure.For example, the CES applying to Anxiety Patients can slow down patient norepinephrine neuron and accelerate the neuron of patient's endorphins, make them reach homoiostasis.For this reason, CES be considered to for the Anxiety Patients that has lost balance than in vivo the patient who loosens in balance there is more theatrical effect.
Potentiation benefit
Collaborative neural acoustics traction software, precursors of neurotransmitters/analog supplement, electricity irritation and the shading eyeglasses of using has a lot of potentiation benefits.CES and neural acoustics traction all promote rapidly the homoiostasis between sympathetic nerve and parasympathetic nervous system, thereby reduce sympathetic system awakening.The utilization of CES together with neural acoustics traction is than using separately neural acoustics traction may obtain the alpha state that promotion is loosened more.The use of neurotransmitter supplement contributes to prevent that presynaptic vesicle is exhausted, and presynaptic vesicle exhaustion can not obtain else if enough precusor amino acids and may occur together with CES.In addition, treat the release that increases inhibitory neurotransmitter for all three kinds.The basic excitatory neuron event that forms serious anxiety has been corrected in the homeostatic recovery of neuro chemistry.After stopped treatment scheme, there is one to the fast quick-recovery of original state, and have no side effect.
The blind research of list of carrying out conformation supports to use the therapeutic scheme of being studied to help the experience of the Anxiety Patients that they perform the operation to collect data, and this operation causes the serious anxiety of their needs calmness in the past.A small sample with the experimenter of the anxiety of bringing out is exposed in complete therapeutic scheme that the treatment of cranium electricity stimulates, neural acoustic software and the amino acid supplements taken, and this amino acid supplements of taking consists of GABA, 5HTP, the theanine with cofactor.In this research, experimenter accepts above-mentioned all parts at second day, and except replacing neural acoustic software by non-neural acoustic software (music of releiving), this is called as dummy treatment.
Research is divided into two stages.Phase I comprises the measurement of GS R.The data of collecting from experimenter in second stage are included in GSR reading and the electroencephalogram that " CZ " obtains.Use ThoughtTechnologies BioGraph ProComp: version 2 .0 records all data.Passage α, θ, β and GSR are selected to for analyzing.Anxiety investigation is amended anxiety list of the check, givenly brings out rear anxiety, and then two treatments, is daily treated afterwards again.
When data are compared, experimenter is exposed to complete treatment, and this complete treatment shows on average than the dummy treatment reduction of 30 generation, on anxiety level and the minimizing of 4.47 microvolts on GSR record.Compare dummy treatment, from the eeg data of neural acoustic software treatment, show ,-0.30 the average range of decrease on β E.E.G power, is illustrated in reduction in vigilance and the increase on loosening.In addition, θ and α E.E.G are presented at the increase on power, θ be+0.7 and α be+1.8.These increase both and represent that experimenter becomes more easily with quiet.This and dummy treatment form contrast, and this dummy treatment is presented at the increase (more vigilance) on β, the reduction (more unquiet) of-0.05 microvolt on θ and the difference (less loosening) of 1.34 microvolts on α.When θ and α increased power.It is lighter that experimenter becomes, and therefore more may during medical treatment or dental operation, be not easy mad making an uproar.
Together with E.E.G and GSR data, requisite is to watch the reduction of experimenter in the anxiety of perception, and this is indicated by the anxiety mark at them and their reflection after research every day.Experimenter's reflection, utilize two therapeutic schemes, they feel more to loosen, but have received that day of complete therapeutic scheme at them, their thought can be let their thinking fly away, and they become than them, receive false neural acoustic software that day easily and much tranquil.They report, they think that after complete treatment pressure and the anxiety that than part treatment, can manage better them cause situation.Neural acoustic software is when when CES is used together with supplement, than more promptly reducing anxiety when independent use CES and the supplement and increase is loosened.
Human Physiology homoiostasis
Balance between autonomic sympathetic nerve and parasympathetic branches is most important for Human Physiology homoiostasis.Autonomic nervous system receives input from central nervous system's part, and central nervous system processes and integrate the stimulation from health and external environment condition.The action of parasympathetic nervous system may be summarized to be has a rest and recovers.Vagus nerve comprises approximately 75% in all parasympathetic fibers.Prevailing sympathetic nervous system response is the driver of much negative physiology and mental status.The consequence of these metabolism has good grounds in the prior art.Calm functional level requires health in the leading state of parasympathetic nervous.
Physiology labelling
Can obtain many physiology labellings, it provides data to analyze clinical system of the present invention in the response of reduction sympathetic nervous system and the effect in anxiety.These labellings comprise: the electroresponse of skin stream, temperature, blood volume pulse, heart rate, heart rate variability (comprising HRV amplitude, SDNN, RMSSD, %LF, %HF and LF/HF) and E.E.G (comprise α, θ, β and δ amplitude, α θ intersects and slow cortical potential).As shown in Figure 3, each in these physiology labellings has been demonstrated specifically response under sympathetic nerve and parasympathetic stimulation (increase or reduce).
Skin stream electroresponse (GSR) is that a kind of measurement is along with the method for the conductivity of the skin of its level of wetness change.This is significant, because sympathetic nervous system is controlled exocrine gland, so skin conductivity is used as the indication of psychology or physiology awakening.In sympathetic activity with between such as frightened and angry emotion awakening, there is relation.GSR is extremely sensitive for the emotion in some.Mankind's exocrine gland receives main signal from the sympathetic choline function fiber of being controlled by neurotransmitter acetylcholine.In measuring GSR, very slight electric current is through skin, and measures salt in sudoriferous duct and the variation of water.Tested body is more waken up emotion, and sweat gland activity is higher, and the conductivity of skin is larger.GSR is along with sympathetic stimulation occur to increase, and along with parasympathetic stimulation reduces.
Skin temperature is another the measuring of sympathetic nerve awakening.Skin temperature is along with sympathetic stimulation reduces, and along with parasympathetic stimulation increases.
Blood volume pulse (BVP) utilizes photoelectric plethysmograph to measure, and photoelectric plethysmograph is a kind of sensor of Noninvasive, for measuring the relative changes in experimenter's finger or the blood volume of temple.Infrared light supply sees through tissue or from tissue reflection, this is detected by phototransistor, and is quantized with arbitrary unit.When blood flow is larger, fewer light is absorbed, and the light intensity that arrives sensor increases.The waveform obtaining from such sensor represents experimenter's BVP, and BVP is that the phase place on blood flow volume changes with each heart beating.Heart rate is only the heart beating quantity of each interval.Heart rate is along with sympathetic stimulation increases, and along with parasympathetic stimulation reduces.BVP increases along with sympathetic stimulation equally, and along with parasympathetic stimulation reduces.
By the heart beating on the interval between successive heartbeat, the difference to heart beating forms heart rate variability (HRV).Conventionally, emotional stress can cause seeming irregular and unsettled cardiac rhythm pattern.Heart rate variability under pressure (HRV) waveform appears as a series of uneven jagged peak, that is, and and incoherent cardiac rhythm pattern.From physiological angle, the signal that this modal representation is produced by the autonomic Liang Ge branch step that differs from one another.This incoherent pattern of the physiological behavior relevant with intense strain can make health inefficiency and move, consumed energy, and on health, produce extra wearing and tearing.If emotional stress is long-term or frequently, this is especially true.During positive emotion, cardiac rhythm pattern becomes high-sequential, looks like the ripple of level and smooth harmony.This is called as relevant cardiac rhythm pattern.For relevant cardiac rhythm, the synchronously behavior in autonomic Liang Ge branch, and the system of health is moved with efficiency and the harmonious degree improving.
HRV data can be identified anxiety and the impact of pressure on cardiovascular system.Interval between heart beating is by it, to can be observed the starting point of parasympathetic nervous and orthosympathetic impact.HRV the measuring to the variation of eartbeat interval that be heart beating.The HRV increasing has been shown having positive clinical meaning, and the HRV reducing is associated with negative clinical effectiveness and condition.In heart beating, be the physiological phenomenon being caused by the several different inputs to sinuatrial node to the variation in eartbeat interval, sinuatrial node is the pacemaker tissue that is arranged in the generation burst of heart right atrium, and is therefore the generator of normal sinus rhythm.Main input is sympathetic nerve and parasympathetic nervous system.Two main fluctuations are hennig-Lommel signs, and low-frequency oscillation is associated with the Mayer wave (waveform on the arteriotony being brought by pressure receptor and chemoreceptor reflex control system) of blood pressure.
For measuring the most widely used method of heart rate variability, be time domain approach and frequency domain method.The heart beating of time domain approach based on having carried out in every way analyzing is to the interval of heart beating or NN.The standard deviation that comprises in these SDNN(NN interval) and the square root of the mean square deviation of RMSSD(N continuous N).These mean the tolerance of sympathetic nerve or parasympathetic impact.The larger parasympathetic impact of mark representative of the increase of these measurements.The standard of these tolerance is: RMSSD27.2+/-12.3 and SDNN136.5+/-33.4.
Measurement with frequency domain method assessment comprises LF, normalized LF, HF, normalized HF and LF/HF ratio.Sympathetic nerve and parasympathetic activity that the rhythm and pace of moving things reflection of HRV in low frequency (LF) scope (between 0.04 to 0.15 hertz) mixes.It is movable that stress increases LF, and be conventionally considered to the labelling of sympathetic nerve modulation.High frequency (HF) scope (between 0.15 to 0.4Hz) comprises the rhythm and pace of moving things that utilizes parasympathetic activity to regulate, and changes corresponding to the N-N being caused by breathing.Dark even breathing activity-stimulat parasympathetic nervous system, and the amplitude of increase HF.It is movable that stress reduces HF.Vagus nerve activity is the main contributions person for high fdrequency component.
Use LF/HF ratio, high numeral means the leading position of sympathetic activity, and low numeral means the leading position of parasympathetic activity.After dark and even breathing, increase and be reflected in the change that parasympathetic nervous regulates.HRV is along with sympathetic stimulation reduces, and along with parasympathetic stimulation increases.Consistent with this result, HRV LF% and LF/HF ratio is along with sympathetic stimulation increases, and along with parasympathetic stimulation reduces.
Various E.E.Gs and clear-headed and sleep state, with the activity of cognitive relevant mental activity, sensation and motion and such as the emotion of fear and anxiety, be associated.β E.E.G is E.E.G the most rapidly, and has reflected normal clear-headed consciousness.β amplitude is along with sympathetic stimulation increases.There is a series of β ripple: low β, easily but vigilance (13-15 hertz); Medium β (approximately 15-19 hertz); And high β, anxiety brain (being associated with frightened and anxiety), shows the frequency of brain wave between 23-38 hertz.α wave table shows a comfortable state loosening, 8-13 hertz, and with loosen, meditation and leisurely and carefree being associated.θ ripple has reflected the state loosening deeply, 4-8 hertz.δ ripple indication sleep state, wherein, signal moves through neuron colony very slowly, 4 hertz of left and right.δ amplitude gradually reduces between sleep period.δ ripple is to the V ripple occurring between sleep period with cortical potential (the following describes) is relevant slowly.
The generation of the α in brain and θ pattern to loosen response relevant.Loosen response and reduce heart rate and blood pressure, relaxed muscle, and increase the oxygen supply to brain.Fight or flight response is accompanied by β brain wave frequency (short arc, altofrequency).Loosen response and reduce heart rate and blood pressure, relaxed muscle, and increase the Oxygen Flow to brain.Loosen response and be very conducive to study and deal with problems, and be accompanied by α (higher amplitude, low-frequency E.E.G) and theta rhythm (larger amplitude, low-frequency E.E.G).Frequency of brain wave is along with sympathetic stimulation increases, and along with parasympathetic stimulation reduces.
α to θ intersects and just in time to occur in before sleep, and the experience of the deep separated hypnosis of loosening is provided.α to θ intersects at the loss of recovering the heart of sleep and the sensation of when and where.This is called as healing district or psychological separation state.State of consciousness is similar to the state of meditation or hypnotic relaxation.α to θ crossing condition is at the just α (8-12 hertz) on the edge of sleep and the state that loosens of the degree of depth in θ (4-8 hertz) scope.This name derives from the behavior of E.E.G.α ripple is conventionally high in amplitude than θ, or more powerful.When the amplitude of α ripple declines and the amplitude of θ rises to it and the point that α ripple intersects, this means that it has become more powerful, quilt is claimed α to θ to intersect.α θ intersects along with sympathetic stimulation reduces, and along with parasympathetic stimulation increases.
Slow cortical potential (SCP) be continue from 300 milliseconds to several seconds, the frequency range lower than 1-2Hz gradually changing in the transmembrane potential of cortex dendron.Nagative potential displacement show mobile or higher can incentive, positive SCP displacement represent neuronic activity reduction can incentive or inhibition.Slow cortical potential displacement in electric negative direction reflects the depolarization of large cortical cell collection, reduces their excited threshold value.SCP is along with sympathetic stimulation increases, and along with parasympathetic stimulation reduces.
Can in Fig. 3, find out, each of these biophysics labellings has contrary response for sympathetic with parasympathetic stimulation.For example, the electroresponse of skin stream increases along with sympathetic stimulation, and reduces with parasympathetic stimulation.Equally, electroencephalogram β amplitude, heart rate variability metrics LF/HF and HRV LF% be along with sympathetic stimulation increases, and along with parasympathetic stimulation reduces.Otherwise skin temperature and heart rate variability amplitude be along with sympathetic stimulation reduces, and along with parasympathetic stimulation increases.
In the research of impact of being assessed therapeutic scheme of the present invention, before being exposed to complete therapeutic scheme and part therapeutic scheme, collect the data set for each of these crucial biological physiology labellings therebetween and afterwards.Make comparisons with part therapeutic scheme, the impact that the present invention combines variety of way with in the individuality using complete treatment Regimen Chemotherapy of the present invention, be created in parasympathetic nervous tension force (relax), hypnosis and sleep state and brain activation in statistical enlarging markedly (SCP minimizing).As shown in Figure 3, biological physiology data acknowledgement, complete treatment scheme of the present invention on biological physiology labelling, produce with the consistent variation of the leading sedation hypnotic effect of parasympathetic nervous.On the contrary, those experimenters that are exposed to part therapeutic scheme do not show the significant variation on physiology labelling.These results have confirmed the novel enhancement effect and its minimizing effect that prove, in rapid minimizing anxiety by the awakening of sympathetic nervous system of complete treatment scheme of the present invention.
In current research, by following manner, test the non-anxiety volunteer of 30 random different health status: be first exposed to complete treatment scheme of the present invention, then be exposed to part therapeutic scheme (after at least 48 hours), to identify the potentiation benefit of therapeutic combination of the present invention.Under study for action, the experimenter of receiving portion therapeutic scheme takes precursors of neurotransmitters/analog supplement, and is received in the cranium electricity treatment stimulation that 100Hz arranges.Those experimenters that accept complete treatment scheme of the present invention accept precursors of neurotransmitters/analog supplement, are arranged on the electric neural acoustics traction software for the treatment of stimulation, sunglasses and having music of cranium of 0.5 hertz.
Before and after, during exposure those experimenters in two kinds of therapeutic schemes, collect crucial bio-physiological signal.From complete and part therapeutic scheme, collect data, and by data with because each baseline that the residual action of complete treatment scheme causes make comparisons.For the residual action comparison base data from complete treatment Regimen Chemotherapy.Object is to assess interior change and the distinctive residual action of processing from complete treatment scheme.Use available statistical analysis software to carry out making great efforts to show the reliability of the data of the parasympathetic nervous tension force that represents increase.
As bright in institute's accompanying drawing digital watch, by following manner, carry out the data analysis for each physiology labelling: during the application of complete and part therapeutic scheme, by a plurality of time diffusion segment tables, levy mark value from the variation of baseline.The analysis of these Study and Comparisons between complete and part therapeutic scheme data set shows, is relevant (nonrandom) trend statistically in both data in special time period and on the persistent period of test.
The experimenter who accepts complete treatment scheme of the present invention is in parasympathetic nervous and more accounts in leading state, and the change in biological physiology labelling as shown in FIG. 4 proves.Fig. 4 shows complete treatment scheme labelling for the response of indication parasympathetic nervous in which kind of degree and has significant effect statistically.Fig. 5 has shown the GSR response of complete treatment scheme 102 and part therapeutic scheme 104.The GSR response of complete treatment scheme 102 presents downward trend, has rapid induction, lasting effect and recovers rapidly to normal.Fig. 6 has shown the BVP amplitude response of complete treatment scheme 106 and part therapeutic scheme 108.Complete treatment scheme 106 BVP amplitude-frequency response increase, there is rapid induction and lasting effect.Fig. 7 A and 7B show the variations in temperature of 146 pairs of complete treatment schemes 148 of baseline.The skin temperature response of complete treatment scheme is risen sharply, and stablizes and maintains the temperature place that compares rising with datum temperature.
Fig. 8 has shown the HRV amplitude response of complete treatment scheme 110 and part therapeutic scheme 112.The HRV amplitude response of complete treatment scheme increases, and shows the accumulative effect having with respect to continuing the remarkable improvement of the baseline after exposure over 48 hours.Fig. 9 has shown the %HF response of complete treatment scheme 118 and part therapeutic scheme 120.The %HF response of complete treatment scheme shows along with turning back to normally increases parasympathetic dominance.Figure 10 has shown the %LF response of complete treatment scheme 122 and part therapeutic scheme 124.The %LF response of complete treatment scheme shows rapid minimizing, lasting effect and recovers rapidly to normal.
Figure 11 has shown the SDNN response of complete treatment scheme 130 and part therapeutic scheme 132.The SDNN response of complete treatment scheme shows that HRV continues in the increase gradually during therapeutic scheme, after exposure surpasses 48 hours afterwards and increases.Some experimenters show within the time period in four weeks increases 30-70%.Figure 12 has shown the RMSSD response of complete treatment scheme 134 and part therapeutic scheme 136.The RMSSD response of complete treatment scheme shows the gradually increase of HRV during therapeutic scheme, in exposure, surpass 48 hours afterwards continues and increases.Some experimenters show within the time period in four weeks increases 30-70%.The heart rate response of complete treatment scheme declines, and the LF/HF ratio of complete treatment scheme reduces.In general, the HRV under complete treatment scheme of the present invention analyzes the coherence of the increase that shows cardiovascular status.
Figure 13 has shown the SCP response of complete treatment scheme 138 and part therapeutic scheme 140.The SCP response of complete treatment scheme shows rapid induction (to the larger blood flow of cortex of frontal lobe), lasting effect and recovers rapidly to normal.Figure 14 has shown the β amplitude response of complete treatment scheme 142 and part therapeutic scheme 144.The β amplitude-frequency response of complete treatment scheme shows the quick minimizing of awakening and the parasympathetic nervous tension force of increase, lasting effect and maintains.Utilize complete treatment scheme of the present invention, the intermediate frequency of E.E.G is reduced to 11.5 hertz from 17.3Hz.
Utilize complete treatment scheme of the present invention, α θ intersection event increases to nine events from an event during section at one time.Result shows, makes comparisons with part therapeutic scheme, and the treatment of complete treatment scheme has significant change statistically on biological physiology labelling, shows, to the more movement of the state of parasympathetic nervous (less awakening, hypnosis), to have larger α E.E.G dominance.This separated tranquilizing soporific traction keeps in the application process of complete treatment scheme of the present invention, and is confirmed in the biological physiology data of collected all categories.Figure 15 has shown the δ amplitude response of complete treatment scheme 126 and part therapeutic scheme 128.The δ amplitude response of complete treatment scheme shows quick hypnosis induction, lasting effect and recovers rapidly normal.Figure 16 shows that the α of complete treatment scheme 114 and part therapeutic scheme 116 surpasses the % response of θ.The % response that the α of complete treatment scheme surpasses θ demonstrates quick hypnosis induction, has lasting effect and quickly recover to normal condition.
Conclusion
From being appreciated that above therapeutic modality of the present invention has treatment application for having the individuality that dentistry and other medical operating are reacted with serious anxiety.Other benefits of the present invention and application will be apparent for those skilled in the art.
Term used " precursors of neurotransmitters/analog supplement " not only refers to natural neurotransmitter supplement in the appended claims, also refer to health be used for synthetic neurotransmitter, forbid the chemical supplement that absorb again or have the effect that is similar to natural neurotransmitter of neurotransmitter.
Although aforesaid detail has been described various embodiment of the present invention, but this area rational technique personnel will recognize, in the situation that do not depart from the spirit and scope of the present invention that limit in the appended claims, can make various changes to the details of equipment of the present invention.Therefore, it should be understood that unless otherwise prescribed, the present invention is not limited to the detail that illustrates and describe here.
Claims (13)
1. a therapy system, for promoting fast the balance of autonomic nervous system (ANS) and healthy maintaining, described therapy system is for being used with patient is collaborative, and described therapy system comprises:
(a) for the neurotransmitter supplement of the therapeutic dose that doses a patient with;
(b) for reducing or eliminating the parts of the environment light intensity on the eyes that are incident on patient;
(c) for the parts allowing patient's support and the position supporting patient of mobile loosening all muscles;
(d) instrument that stimulates (CES) for apply the treatment of cranium electricity for patient; And
(e), for apply the instrument of neural acoustics traction program for patient, each ear that described neural acoustics traction program is patient generates respectively and the signal tone of two different frequencies that side by side present.
2. therapy system according to claim 1, wherein, described neurotransmitter supplement comprise the similar thing supplement of neurotransmitter.
3. therapy system according to claim 2, wherein, the similar thing supplement of described neurotransmitter comprise γ-aminobutyric acid (GABA) preparation.
4. therapy system according to claim 2, wherein, the similar thing supplement of described neurotransmitter comprise L-thiamine preparation.
5. therapy system according to claim 2, wherein, the similar thing supplement of described neurotransmitter comprise CTH preparation.
6. therapy system according to claim 2, wherein, the similar thing supplement of described neurotransmitter comprise phenyl-gamma-aminobutyric acid preparation.
7. therapy system according to claim 1, wherein, described neurotransmitter supplement comprise precursors of neurotransmitters supplement.
8. therapy system according to claim 7, wherein, described precursors of neurotransmitters supplement comprise 5HTP.
9. therapy system according to claim 7, wherein, described precursors of neurotransmitters supplement comprise dehydroepiandrosterone (DHEA) preparation.
10. therapy system according to claim 1, wherein, described neurotransmitter supplement have and are suitable for oral form.
11. therapy system according to claim 1, wherein, described neurotransmitter supplement have the form that is suitable for sublingual administration administration.
12. therapy system according to claim 1, wherein, described neurotransmitter supplement have the form that is suitable for transdermal administration.
13. therapy system according to claim 1, wherein, described neurotransmitter supplement comprise the preparation of at least one compound that is selected from the group that comprises following composition: γ-aminobutyric acid (GABA), 5HTP and dehydroepiandrosterone (DHEA).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/162,446 | 2011-06-16 | ||
| US13/162,446 US9079030B2 (en) | 2004-12-22 | 2011-06-16 | Systems and methods for balancing and maintaining the health of the human autonomic nervous system |
| PCT/US2011/042360 WO2012173634A1 (en) | 2011-06-16 | 2011-06-29 | Systems and methods for balancing and maintaining the health of the human autonomic nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103547240A true CN103547240A (en) | 2014-01-29 |
| CN103547240B CN103547240B (en) | 2016-03-30 |
Family
ID=47357391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180070951.0A Active CN103547240B (en) | 2011-06-16 | 2011-06-29 | For the autonomic balance of the mankind and the system and method maintaining health |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103547240B (en) |
| WO (1) | WO2012173634A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818959A (en) * | 2018-03-08 | 2020-10-23 | 西铁城时计株式会社 | Heart rate adjusting device |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
| US20050027284A1 (en) * | 2003-06-19 | 2005-02-03 | Advanced Neuromodulation Systems, Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
| CN1592616A (en) * | 2000-11-20 | 2005-03-09 | H·隆德贝克有限公司 | GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| WO2006071268A1 (en) * | 2004-12-22 | 2006-07-06 | Staffel Edward R | Dental/medical anxiety/phobia remediation protocol |
| US20070203432A1 (en) * | 2003-12-17 | 2007-08-30 | Mcnew Barry | Apparatus, system, and method for creating an individually balanceable environment of sound and light |
| CN102083453A (en) * | 2008-06-06 | 2011-06-01 | 洛林国立高等理工学院 | Anxiolytic composition containing [alpha]s1-casein-derived peptides |
-
2011
- 2011-06-29 WO PCT/US2011/042360 patent/WO2012173634A1/en active Application Filing
- 2011-06-29 CN CN201180070951.0A patent/CN103547240B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
| CN1592616A (en) * | 2000-11-20 | 2005-03-09 | H·隆德贝克有限公司 | GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| US20050027284A1 (en) * | 2003-06-19 | 2005-02-03 | Advanced Neuromodulation Systems, Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
| US20070203432A1 (en) * | 2003-12-17 | 2007-08-30 | Mcnew Barry | Apparatus, system, and method for creating an individually balanceable environment of sound and light |
| WO2006071268A1 (en) * | 2004-12-22 | 2006-07-06 | Staffel Edward R | Dental/medical anxiety/phobia remediation protocol |
| CN102083453A (en) * | 2008-06-06 | 2011-06-01 | 洛林国立高等理工学院 | Anxiolytic composition containing [alpha]s1-casein-derived peptides |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818959A (en) * | 2018-03-08 | 2020-10-23 | 西铁城时计株式会社 | Heart rate adjusting device |
| CN111818959B (en) * | 2018-03-08 | 2022-09-09 | 西铁城时计株式会社 | Heart rate adjusting device |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012173634A1 (en) | 2012-12-20 |
| CN103547240B (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9079030B2 (en) | Systems and methods for balancing and maintaining the health of the human autonomic nervous system | |
| Teale et al. | Cortical source estimates of gamma band amplitude and phase are different in schizophrenia | |
| Grimaldi et al. | Neurostimulation techniques to enhance sleep and improve cognition in aging | |
| KR20140037803A (en) | Device, system and methods for the treatment of medical disorders | |
| Scheuermaier et al. | Improved cognitive morning performance in healthy older adults following blue-enriched light exposure on the previous evening | |
| WO2006071268A1 (en) | Dental/medical anxiety/phobia remediation protocol | |
| WO2019082180A1 (en) | An electrical stimulation device and methods of using the device | |
| Paleczny et al. | Inspiratory-and expiratory-gated transcutaneous vagus nerve stimulation have different effects on heart rate in healthy subjects: preliminary results | |
| Heinz et al. | Effects of transcranial direct current stimulation (tDCS) and exercises treadmill on autonomic modulation of hemiparetic patients due to stroke—clinic test, controlled, randomized, double-blind | |
| Chen et al. | Autonomic/central coupling benefits working memory in healthy young adults | |
| Laufer et al. | Psychophysiological effects of coloured lighting on older adults | |
| Staley et al. | Modulatory effects of respiratory-gated auricular vagal nerve stimulation on cardiovagal activity in hypertension | |
| Clauss | Disorders of consciousness and pharmaceuticals that act on oxygen based amino acid and monoamine neurotransmitter pathways of the brain | |
| Liu et al. | Psychological and physiological effects of 24-style taijiquan | |
| CN103547240B (en) | For the autonomic balance of the mankind and the system and method maintaining health | |
| RU2405591C1 (en) | Method of treating patients with stage i-ii hypertensive discirculatory encephalopathy | |
| US20210100491A1 (en) | System for use in improving cognitive function | |
| Ruiz-Tristan et al. | Estradiol and Progesterone as key modulators of central systems implicated in schizophrenia | |
| US11536965B2 (en) | Technologies for multi-randomized audio-visual entrainment | |
| RU2806480C1 (en) | METHOD OF OPTIMIZING FUNCTIONAL STATE OF BODY OF ATHLETES USING NEUROBIOFEEDBACK ON β BRAIN RHYTHM | |
| US20230381509A1 (en) | Use of Non-Invasive Sensory Systems to Titrate Cranial Nerve Stimulation to Enhance Brain Clearance Closed-Loop | |
| Levkov | The Effects of Dance on Motor and Non-Motor Functions, and Resting State Electroencephalography in Individuals With Parkinson's Disease and Age-Matched Controls | |
| Yuminaga et al. | Changes in Electroencephalography Signals During Massage | |
| Omlin | The effect of vestibular stimulation on sleep and cardio-respiratory functions | |
| Tukaiev et al. | Non-invasive vagus nerve stimulation attenuates the burnout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |